Good Quality Price Powder Nafamostat 81525-10-2

Why choose us1. Strong backup of facotry: high R&D ability, favorable quality and competitive price
2. Stock avaliability
3. Flexible business way, like payment term and product delivery
4. Fast response 24*7
5. Agood troubleshooter/very positive attitude for after serviceDescription

Product name

Nafamostat

CAS NO.81525-10-2Synonyms

Nafamostat

CategoryPharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.Standardpurity:>99%AppearanceNafamostat powderShelf life2 yearsUsage

Nafamostat is afast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin.

StorageNafamostat should be stored in awell-closed container at low temperature, keep away from moisture, heat and light.
IntroductionNafamostat is used for acute pancreatitis and acute exacerbation of chronic pancreatitis. Also used for hemodialysis, coronary artery bypass grafting, anticoagulation during liver resection, and glomerulonephritis with systemic lupus erythematosus or mixed cryoglobulinemia (Cryoglobulimemia). It is asynthetic serine proteolytic enzyme inhibitor with anticoagulant, anti-plasmin and anti-platelet aggregation. The drug is asynthetic serine proteolytic enzyme inhibitor, which has anticoagulant, anti-fibrinolytic enzyme and anti-platelet aggregation effects.FunctionFor acute pancreatitis, acute exacerbation of chronic pancreatitis. Also used for hemodialysis, coronary artery bypass grafting, anticoagulation during liver resection, and glomerulonephritis with systemic lupus erythematosus or mixed cryoglobulinemia.
The drug is asynthetic serine proteolytic enzyme inhibitor, which has anticoagulant, anti-fibrinolytic enzyme and anti-platelet aggregation effects. The specific effects are as follows: 1. Enzyme inhibition: The drug is applied to trypsin, kallikrein (vasopressin), plasmin, fibrin, and CL-r, CL-s and other classic pathways of the complement system. Protease-like serine protease has astrong selective inhibition; it also inhibits phospholipase A2. Trypsin binding to α2-macroglobulin is also inhibited in vitro. 2. Effects on experimental acute pancreatitis: Intravenous infusion of the drug into rats and rabbits, various experimental pancreatitis caused by retrograde injection of trypsin, enterokinase and endotoxin through the pancreatic duct can inhibit pancreatitis The resulting increase in trypsin activity and the activity of enzymes entering the blood and reduce mortality. 3. Effect on kallikrein-kinin system: Administration of this drug to patients with pancreatitis can improve the reduction of the total amount of kininogens caused by kallikrein activation. 4. Effect on blood coagulation and fibrinolytic system: The drug produces anticoagulant action by inhibiting fibrin and factor XIIa and Xa. In vitro experiments have also found that this drug can inhibit platelet aggregation. In animal experiments, intravenous administration of the drug prolongs the partial thromboplastin (thrombin) time and urokinase-activated fibrin block dissolution time in rabbits. Because heparin has the risk of increasing bleeding, this drug can be used as asubstitute for heparin. 5. Effect on the complement system: For guinea pigs with systemic Forsman heterosis shock caused by intravenous hemolysin, oral and intravenous injections can prolong their lives.
Contact:Jenny Lu
Mobile:86/008618715606860